down arrow

Theravance Biopharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG8807B1068
USD
18.70
0.27 (1.47%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Net Sales
26.20
15.39
18.75
16.87
14.26
14.50
17.57
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
26.20
15.39
18.75
16.87
14.26
14.50
17.57
Raw Material Cost
1.35
1.38
1.36
1.56
1.56
1.53
1.72
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.66
0.64
0.64
0.63
0.64
0.63
0.62
Selling and Distribution Expenses
17.49
19.71
17.45
15.75
15.93
15.64
14.06
Other Expenses
0.94
1.04
0.85
0.82
0.89
0.79
0.74
Total Expenditure (Excl Depreciation)
28.92
32.13
27.95
26.14
27.01
25.71
23.81
Operating Profit (PBDIT) excl Other Income
-2.7
-16.7
-9.200000000000001
-9.3
-12.8
-11.200000000000001
-6.2
Other Income
76.59
3.24
0.90
1.42
1.13
1.43
1.85
Operating Profit (PBDIT)
75.22
-12.12
-6.93
-6.30
-10.07
-8.24
-2.67
Interest
0.66
0.64
0.64
0.63
0.64
0.63
0.62
Exceptional Items
0.00
0.00
0.00
-1.56
-2.95
0.00
0.00
Gross Profit (PBDT)
24.85
14.01
17.39
15.31
12.70
12.97
15.85
Depreciation
1.35
1.38
1.36
1.56
1.56
1.53
1.72
Profit Before Tax
73.21
-14.14
-8.94
-10.05
-15.22
-10.40
-5.02
Tax
18.37
-0.56
6.59
2.65
1.31
1.26
3.49
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
54.84
-13.58
-15.53
-12.70
-16.53
-11.66
-8.51
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
54.84
-13.58
-15.53
-12.70
-16.53
-11.66
-8.51
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
54.84
-13.58
-15.53
-12.70
-16.53
-11.66
-8.51
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
224.85
165.98
175.54
185.65
193.69
204.87
213.00
Earnings per share (EPS)
1.08
-0.27
-0.31
-0.26
-0.34
-0.24
-0.17
Diluted Earnings per share
1.08
-0.27
-0.31
-0.26
-0.34
-0.24
-0.17
Operating Profit Margin (Excl OI)
-10.4%
-108.77%
-49.06%
-54.99%
-89.46%
-77.27%
-35.53%
Gross Profit Margin
284.62%
-82.92%
-40.4%
-50.36%
-95.84%
-61.15%
-18.78%
PAT Margin
209.33%
-88.24%
-82.8%
-75.28%
-115.94%
-80.42%
-48.45%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Jun 2025 is 83.22% vs 4.38% in Jun 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Jun 2025 is 432.12% vs -5.77% in Jun 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Jun 2025 is 87.50% vs 17.65% in Jun 2024

stock-summary

Interest

YoY Growth in quarter ended Jun 2025 is 16.67% vs 0.00% in Jun 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024

Compare Quarterly Results Of Theravance Biopharma, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
26.20
1.78
24.42
1,371.91%
Other Operating Income
0.00
0.00
0.00
Total Operating income
26.20
1.78
24.42
1,371.91%
Raw Material Cost
1.35
1.85
-0.50
-27.03%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.66
0.00
0.66
Selling and Distribution Expenses
17.49
5.39
12.10
224.49%
Other Expenses
0.94
1.14
-0.20
-17.54%
Total Expenditure (Excl Depreciation)
28.92
18.69
10.23
54.74%
Operating Profit (PBDIT) excl Other Income
-2.73
-16.91
14.18
83.86%
Other Income
76.59
2.98
73.61
2,470.13%
Operating Profit (PBDIT)
75.22
-13.72
88.94
648.25%
Interest
0.66
0.00
0.66
Exceptional Items
0.00
-1.50
1.50
100.00%
Gross Profit (PBDT)
24.85
-0.07
24.92
35,600.00%
Depreciation
1.35
0.21
1.14
542.86%
Profit Before Tax
73.21
-15.43
88.64
574.47%
Tax
18.37
0.00
18.37
Provisions and contingencies
0
0
0.00
Profit After Tax
54.84
-15.43
70.27
455.41%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
54.84
-15.43
70.27
455.41%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
54.84
-15.43
70.27
455.41%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
224.85
131.74
93.11
70.68%
Earnings per share (EPS)
1.08
-0.13
1.21
930.77%
Diluted Earnings per share
1.08
-0.13
1.21
930.77%
Operating Profit Margin (Excl OI)
-10.40%
-951.49%
0.00
941.09%
Gross Profit Margin
284.62%
-856.22%
0.00
1,140.84%
PAT Margin
209.33%
-868.26%
0.00
1,077.59%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 2.62 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 70.13% vs -18.09% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 83.22% vs 4.38% in Jun 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 5.48 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 502.94% vs 12.26% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 432.12% vs -5.77% in Jun 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -0.14 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 90.91% vs -97.44% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 87.50% vs 17.65% in Jun 2024

Quarterly - Interest
Interest 0.07 Million
in Jun 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Jun 2025 is 16.67% vs 0.00% in Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 is 16.67% vs 0.00% in Jun 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -10.40%
in Jun 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Jun 2025 has improved from Mar 2025

stock-summary

YoY Growth in quarter ended Jun 2025 has improved from Jun 2024

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."